TWI228123B - Antithrombotic compounds - Google Patents

Antithrombotic compounds Download PDF

Info

Publication number
TWI228123B
TWI228123B TW087105306A TW87105306A TWI228123B TW I228123 B TWI228123 B TW I228123B TW 087105306 A TW087105306 A TW 087105306A TW 87105306 A TW87105306 A TW 87105306A TW I228123 B TWI228123 B TW I228123B
Authority
TW
Taiwan
Prior art keywords
amino
compound
ministry
cns
group
Prior art date
Application number
TW087105306A
Other languages
English (en)
Chinese (zh)
Inventor
Boeckel Constant Adriaan A Van
Galen Philippus Johannes M Van
Johannes Bernardus Ma Rewinkel
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of TWI228123B publication Critical patent/TWI228123B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW087105306A 1997-04-24 1998-04-08 Antithrombotic compounds TWI228123B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201227 1997-04-24

Publications (1)

Publication Number Publication Date
TWI228123B true TWI228123B (en) 2005-02-21

Family

ID=8228249

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087105306A TWI228123B (en) 1997-04-24 1998-04-08 Antithrombotic compounds

Country Status (10)

Country Link
US (4) US6194409B1 (enExample)
EP (2) EP1505062A1 (enExample)
JP (1) JP4392061B2 (enExample)
AR (1) AR012588A1 (enExample)
AU (1) AU7648698A (enExample)
CA (1) CA2287558C (enExample)
IL (1) IL123986A (enExample)
TW (1) TWI228123B (enExample)
WO (1) WO1998047876A1 (enExample)
ZA (1) ZA983176B (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602864B1 (en) * 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
EP1009758B1 (en) * 1997-08-29 2005-06-01 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
AU753675B2 (en) * 1998-03-19 2002-10-24 Ajinomoto Co., Inc. Aminoisoquinoline derivatives
WO2000009480A1 (en) * 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
ES2209337T3 (es) 1998-08-14 2004-06-16 Pfizer Inc. Agentes antitromboticos.
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
EP1058549A4 (en) * 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
KR20000047461A (ko) * 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
MXPA01011805A (es) * 1999-05-19 2003-09-04 Pharmacia Corp Aril y heteroaril piridonas policiclicas, substituidas utiles para la inhibicion selectiva de la cascada de coagulacion.
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
WO2000071493A2 (en) * 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
GB9929552D0 (en) * 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
WO2000076970A2 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
JP2003519120A (ja) * 1999-12-27 2003-06-17 オーソーマクニール ファーマシューティカル， インコーポレイテッド 卵胞刺激ホルモンの拮抗物質としての置換したアミノアルキルアミド誘導体
WO2001068605A1 (en) 2000-03-13 2001-09-20 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
EP1267876A1 (en) 2000-03-23 2003-01-02 Merck & Co., Inc. Thrombin inhibitors
EP1268428A2 (en) 2000-04-05 2003-01-02 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
EP1274676A2 (en) 2000-04-17 2003-01-15 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
SI20582A (sl) * 2000-05-05 2001-12-31 Univerza V Ljubljani Novi inhibitorji trombina, njihova priprava in uporaba
AU2001256733A1 (en) * 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
WO2001087851A1 (en) * 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7074934B2 (en) 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
WO2002004423A1 (en) 2000-07-12 2002-01-17 Akzo Nobel N.V. Thrombin inhibitors comprising an aminoisoquinoline group
US6906192B2 (en) 2000-11-07 2005-06-14 Bristol Myers Squibb Company Processes for the preparation of acid derivatives useful as serine protease inhibitors
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
WO2002042272A2 (en) 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
JP2004518688A (ja) 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
US6905813B2 (en) * 2001-08-29 2005-06-14 Chugai Photo Chemical Co., Ltd. Processing agent for silver halide color photosensitive material and processing method thereof
MXPA04003170A (es) 2001-10-03 2004-07-08 Pharmacia Corp Compuestos policiclicos, sustituidos, provisto de 5 miembros, utiles para la inhibicion selectiva de la cascada de coagulacion.
CA2462305A1 (en) 2001-10-03 2003-04-10 Michael S. South 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
WO2004072102A2 (en) * 2003-02-11 2004-08-26 Bristol-Myers Squibb Company Benzene acetamide compounds useful as serine protease inhibitors
US7122559B2 (en) * 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
US20070179155A1 (en) * 2003-06-20 2007-08-02 Brian Smith N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
JPWO2006064780A1 (ja) * 2004-12-14 2008-06-12 塩野義製薬株式会社 便秘治療剤
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
ATE479676T1 (de) * 2005-01-10 2010-09-15 Bristol Myers Squibb Co Als antikoagulanzien verwendbare phenylglycinamid-derivate
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE602006011752D1 (de) * 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
TWI389899B (zh) * 2006-08-08 2013-03-21 Msd Oss Bv 具口服活性之凝血酶抑制劑
AR063258A1 (es) * 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2008144483A2 (en) * 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
EP2138495A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138492A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138498A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
CN101684077B (zh) 2008-09-24 2013-01-02 浙江九洲药业股份有限公司 N-酰基联苯丙氨酸的制备方法
CN101774941A (zh) 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
CN101555211B (zh) * 2009-05-13 2012-01-25 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的化学合成方法
EP2480523B1 (en) * 2009-09-23 2017-03-01 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Process for manufacture of n-acylbphenyl alanine
WO2012015949A2 (en) * 2010-07-29 2012-02-02 Joule Unlimited Technologies, Inc. Methods and compositions for improving yields of reduced products of photosynthetic microorganisms
MY182666A (en) 2010-11-05 2021-01-28 Senomyx Inc Compounds useful as modulators of trpm8
EP2606893A1 (en) * 2011-12-21 2013-06-26 Sanofi Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application
WO2014188211A1 (en) 2013-05-23 2014-11-27 Kalvista Pharmaceuticals Limited Heterocyclic derivates
ITUB20150417A1 (it) * 2015-05-08 2016-11-08 Dipharma Francis Srl Procedimento per la preparazione di composti piperidinici
JP6865743B2 (ja) 2015-10-01 2021-04-28 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｔｒｐｍ８の活性調節因子として有用な化合物
GB201805174D0 (en) * 2018-03-29 2018-05-16 Univ Leeds Innovations Ltd Compounds
GB201807014D0 (en) * 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
SMT202400527T1 (it) 2019-07-01 2025-01-14 Tonix Pharma Ltd Anticorpi anti-cd154 e loro usi
CA3147564A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
CN114258392A (zh) * 2019-08-21 2022-03-29 卡尔维斯塔制药有限公司 酶抑制剂
AR121715A1 (es) * 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
CA3207098A1 (en) 2021-01-06 2022-07-14 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2024044098A2 (en) * 2022-08-23 2024-02-29 Alexion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies
CN119954681A (zh) * 2025-02-05 2025-05-09 南京工业大学 一种小分子光交联剂、制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920703558A (ko) 1990-11-15 1992-12-18 원본미기재 메타-치환 페닐알라닌 유도체
WO1992016549A1 (de) * 1991-03-18 1992-10-01 Pentapharm Ag Para-substituierte phenylalanin-derivate
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9322976D0 (en) * 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
EP0944386B1 (en) * 1996-12-13 2002-09-18 Aventis Pharmaceuticals Inc. Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

Also Published As

Publication number Publication date
AU7648698A (en) 1998-11-13
AR012588A1 (es) 2000-11-08
US6432955B1 (en) 2002-08-13
EP0975600A1 (en) 2000-02-02
US20030130270A1 (en) 2003-07-10
EP1505062A1 (en) 2005-02-09
JP2001523240A (ja) 2001-11-20
IL123986A (en) 2011-10-31
CA2287558C (en) 2009-09-08
ZA983176B (en) 1998-10-21
IL123986A0 (en) 1998-12-06
JP4392061B2 (ja) 2009-12-24
CA2287558A1 (en) 1998-10-29
US6797710B2 (en) 2004-09-28
WO1998047876A1 (en) 1998-10-29
US6444672B1 (en) 2002-09-03
US6194409B1 (en) 2001-02-27

Similar Documents

Publication Publication Date Title
TWI228123B (en) Antithrombotic compounds
RU2232760C2 (ru) Ингибитор сериновых протеаз и фармацевтическая композиция на его основе
TW487708B (en) Acylguanidine derivatives and their use as serine protease inhibitors
CA2320378A1 (en) Cyclic dipeptides and azetidinone compounds and their use in treating cns injury and neurodegenerative disorders
CN102127053A (zh) 二肽基肽酶抑制剂
JP2846963B2 (ja) 抗血栓アミジノテトラヒドロピリジルアラニン誘導体
EP1077218B1 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
CA2184824A1 (en) Bradykinin antagonist peptides incorporating n-substituted glycines
TW202330539A (zh) 用於治療、預防或管理過度增生性病症之化合物、醫藥組合物及方法
US20020068695A1 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
JPH11507366A (ja) トロンビン阻害剤類
CZ108496A3 (en) Anti-thrombotic azacycloalkylalkanoyl peptides and pseudopeptides
WO1999001472A1 (de) Cyclische azapeptide mit angiogener wirkung
US7910556B2 (en) PAR-2 agonist
WO2023057813A1 (en) Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
CN109563136A (zh) 作为C5a受体拮抗剂的环肽
WO1997010261A1 (fr) Derives peptidiques
EP1864994B1 (en) Par-2 agonist
WO2007038169A2 (en) Multi-valent guanidinium compounds for molecular translocation across cellular membranes and epithelial tissues
JP3874455B2 (ja) フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤
LT3681B (en) N-acyl-alpha-amino acid derivatives, method for producting thereof,pharmaceutical compositions and preparing them
MXPA01000437A (en) Diacylhydrazine derivatives as integrin inhibitors
JPWO2000063171A1 (ja) 三環性化合物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees